Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
SARS-CoV-2 anti-spike antibodies after a fourth dose of COVID-19 vaccine in adult solid-organ transplant recipients

Quentin Perrier, Julien Lupo, Théophile Gerster, Caroline Augier, Loïc Falque, Lionel Rostaing, Laurent Pelletier, Pierrick Bedouch, Myriam Blanc, Christel Saint-Raymond, Aude Boignard, Agnès Bonadona, Johan Noble, Olivier Epaulard

Pharmacy Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Laboratory of Fundamental and Applied Bioenergetic (LBFA), INSERM U1055, Grenoble, France
Virology Laboratory, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Laboratoire de Biologie Structurale (IBS), CEA, CNRS, Grenoble, France
Hepatogastroenterology Department, Grenoble Alpes University Hospital, Grenoble, France
Cardiology Department, Grenoble Alpes University Hospital, Grenoble, France
Pneumology and Physiology Department, Grenoble Alpes University Hospital, Grenoble, France
Nephrology, Hemodialysis, Apheresis and Kidney Transplantation Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Grenoble, France
Virology Laboratory, Grenoble Alpes University Hospital, Grenoble, France
Infectious Diseases Department, Grenoble Alpes University Hospital and Univ. Grenoble Alpes, Groupe de Recherche en Infectiologie Clinique, CIC-1406, INSERM, Grenoble, France

ABSTRACT

Background: A fourth dose of SARS-CoV-2 vaccine is recommended in solid-organ transplant (SOT) recipients, but the immunogenicity is poorly known.

Methods: We conducted a retrospective, observational, monocentric study between the 1st January 2021 and 31st March 2022 of the anti-Spike antibody titers after one to four doses of vaccine in SOT.

Results: 825 SOT were included. Median age at first vaccine injection was 61.2 (IQR 50.9–69.3) years; 66.7 % were male; 63.4 % had received four vaccine doses. The proportion of participants with a strong humoral response (>260 BAU/mL) increased with the number of vaccine doses: 10.6 % after the 1st dose (D1), 35.1 % after the 2nd (D2), 48.5 % after the 3rd (D3), and 65.1 % after the 4th (D4) (p < 0.001). Among the tested patients, the proportion with a detectable humoral response was significantly higher after D4 than after D3 (47 % vs 22 %, p = 0.01). Liver transplant recipients had more frequently a strong humoral response after D2, D3 and D4 (OR = 5.3, 3.7 and 6.6 respectively when compared with other organ transplant recipients, p < 0.001). In kidney transplant recipients, belatacept-containing regimen was associated with a lower rate of detectable humoral (9 % vs 40 %, p = 0.025) after D3, but there was no statistical difference after D4.

Conclusion: A fourth dose should be proposed to SOT recipients who did not developed an immune response after 3 doses. Kidney transplant recipients receiving belatacept have a poorer, although frequently detectable response.

© 2022 Elsevier Ltd. All rights reserved.

1. Introduction

The current COVID-19 pandemic has affected solid-organ transplantation (SOT) recipients on several levels. Firstly, it caused temporary suspension of transplant programs in 2020; secondly, SARS-CoV-2 infection is associated in SOT recipients with higher morbidity and mortality compared to the general population [1,2]. Thus, for this at-risk population and others, the elaboration and validation of vaccines brought a lot of hope. In the European Union, between December 2020 and March 2021, four COVID-19 vaccines have received marketing authorization: BNT162b2 from Pfizer-BioNTech; mRNA-1273 from Moderna; AZD1222 from Oxford-AstraZeneca; and Ad26COV2-S from Janssen. In the initial clinical trials, these vaccines demonstrated great efficacy at reducing symptomatic infection by 66–95 % in healthy volunteers after
two doses [3–5], and “real-life” data confirmed they efficiently prevented severe forms by 90–95 %; later, a booster dose showed an efficacy of ~90–95 % for maintaining this protection over time (for mRNA platforms) [6]. During the year 2021, both the emergence of variants of concern (Delta then Omicron) and the waning of antibody titers after two doses, resulted in decreased effectiveness against SARS-CoV-2 infection; however, vaccine-induced protection against severe forms of COVID-19 is still high. Recently, a study conducted in Israel on patients aged >60 years reported the benefits of a fourth vaccine dose in reducing the risk of severe COVID-19 [7].

It is well established that lower antibody titers are observed in immunocompromised patients after vaccination (e.g., for hepatitis B virus or pneumococcal vaccines [8,9]). Unfortunately, SOT recipients were excluded from the pivotal trials of the COVID-19 vaccines. In 2021, several studies reported a decreased antibody response to COVID-19 vaccines after one [10] or two [11–14] doses in SOT recipients. To overcome this limitation, a third dose (D3) was recommended for immunocompromised patients, such as transplant recipients (before it was also recommended for immunocompetent subjects) and, in some countries (including France), even a fourth dose (D4). Higher seroconversion rates were reported after D3 (67.9 % vs 41.4 % after D2) in 396 SOT recipients vaccinated by the Pfizer-BioNTech vaccine [15]. More recently, some teams have reported case series (37 patients [16], 18 patients [17], 67 patients [18], 49 patients [19], 92 patients [20] and 188 patients [21]) of SOT recipients where D4 slightly improved the antibody response.

We aimed to assess the immunogenicity of COVID-19 vaccines in a larger population of SOT recipients after one to four doses of COVID-19 vaccine.

2. Materials and methods

2.1. Data collection

We conducted a retrospective, observational, monocentric study. We included all adults from our center (Grenoble-Alpes University Hospital, France) that had received a heart, kidney, liver, or lung transplantation, and that had received at least one dose of COVID-19 vaccine, and with at least one measure of serum SARS-CoV-2 anti-spike antibodies after a vaccine dose. Patients with a past documented SARS-CoV-2 infection were excluded from the study, as patient with detectable SARS-CoV-2 anti-spike antibodies before the first dose of vaccine. Data were collected between the 1st January 2021 and 31st March 2022. All patients had previously given their consent for the retrospective use of their hospital-care data. This study falls within the scope of the French Reference Methodology MR-004 according to the 2016–41 law dated 26 January 2016.

2.2. Anti-spike antibody level

Due to the prolonged period considered (from January 2021 to March 2022), the quantification of anti-SARS-CoV-2 Spike antibodies was obtained using diverse immunoassays using the receptor binding domain (RBD) as target antigen, and available in different city and hospital laboratories: the Wantai SARS-CoV-2 Ab ELISA detecting total antibodies (Beijing Wantai Biological Pharmacy Enterprise), the VIDAS SARS-CoV-2 IgG II ELFA assay (Biomerieux), the Alinity i SARS-CoV-2 IgG II Quant assay (Abbott), the Elecsys anti-SARS-CoV-2 S assay detecting total antibodies (Roche Diagnostics) and the Atellica sCOVG IgG assay (Siemens Healthineers). The Hospital virology laboratory used the Wantai ELISA with a TECAN Evolyser device. A linear relationship between sample-to-cutoff (S/CO) and antibody concentration was evaluated for samples in the 1.25 to 15 S/CO range. Samples with S/CO over 15 were diluted 1/40 in phosphate-buffered saline containing 7.5 % bovine serum albumin. We used the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin (human) as reference for anti-SARS-CoV-2 Ab titers (NIBSC code: 20/136). This standard is supplied as a vial containing 250 IU for neutralizing antibody activity equivalent to 250 binding antibody units (BAU) for binding antibody assays. Using the Wantai ELISA on the TECAN platform, we found a conversion factor of 0.75 between the results expressed in S/CO and BAU (1 S/CO = 0.75 BAU) which was similar as previous reports using the same ELISA reagent [22]. All results of SARS-CoV2 anti-spike antibody levels were expressed as binding antigen units (BAU)/mL according to the manufacturers’ (Biomerieux, Abbott, Roche, Siemens) and WHO recommendations [23]. All these assays exploring anti-Spike (RBD) antibody levels showed a good correlation with the titers of anti-SARS-CoV-2 neutralizing antibodies [22,24,25].

2.3. Anti-spike serological profile

A threshold of 260 BAU/mL has been proposed by the French health authorities to classify the patients as responders or low responders to COVID-19 vaccines, in reference to a study assessing the correlates of protection in immunocompetent patients against the Alpha B.1.1.7 strain [26]. In France this threshold still defines the immunocompromised patients eligible to a treatment with anti-SARS-CoV-2 neutralizing monoclonal antibodies. Therefore, the serological status of patients was classified as 1) seronegative if the anti-spike antibody level was below the limit of detection in the assay, 2) a weak humoral response if antibodies were detectable but under the threshold of 260 BAU/mL, or 3) strong humoral response if antibody level was > 260 BAU/mL.

2.4. Immunosuppressive regimen

For kidney-transplant recipients, all patients received 1 g/day of mycophenolate mofetil (MMF) and, prednisolone was given at the dose of 10 mg/day and stopped at 30 post-transplant. If kidney allograft surveillance biopsy at 3 months post-transplant was normal prednisone was stopped. Tacrolimus was adjusted to achieve residual levels of 8–12 ng/mL the first month, and then 4–8 ng/mL. Moreover, in case of nephrotoxicity, late-seroconversion to belatacept was possible. Finally, the immunosuppressive regimen at the time of vaccination was recorded as receiving or not receiving belatacept.

For liver-transplant recipients, all patient received 2 g/day of MMF and in absence of allograft rejection, it was stopped at 6 months post-transplant. Prednisolone was given at the dose of 10 mg/day and stopped at 60 days post-transplant. Tacrolimus was adjusted to achieve residual levels of 8–12 ng/mL the first month, 6–9 ng/mL the first year, 3–5 ng/mL the second year and finally 2–5 ng/mL five years post-transplant. Moreover, in case of nephrotoxicity, adjunction of everolimus could be possible in order to reduce the dose of tacrolimus.

For heart-transplant recipients, all patient received 2 g/day of MMF to achieve an area under curve at 45 during the first year post transplant and 35 after. Prednisolone was given 10 mg/day and stopped between 12 and 18 months post-transplant. Cyclosporine A was adjusted to achieve residual levels of 250–300 ng/mL the first two months, 200–250 ng/mL the first year, and then 150–200 ng/mL. In case of toxicity cyclosporine A could be switch by tacrolimus that was adjusted to achieve residual levels of 10–15 ng/mL the first two months, 8–10 ng/mL the first year, and then 5–8 ng/mL. Moreover, in case of nephrotoxicity, adjunction of everolimus could be possible in order to reduce the dose of tacrolimus.
For lung-transplant recipients, all patient received 2 g/day of MMF and prednisolone 0.1 mg/kg/day. Tacrolimus was adjusted to achieve trough levels of 10–15 ng/mL for the first three month, and then 5–10 ng/mL. Moreover, in case of nephrotoxicity, adjunction of everolimus could be possible in order to reduce the dose of tacrolimus.

2.5. Statistical analyses

Categorical variables are expressed as their frequency (and percentages); quantitative variables are expressed as the median (with interquartile ranges). Patient characteristics were compared using ANOVA for continuous data (or non-parametric tests when normality was not met) and the chi-square test for categorical data (or Fisher’s exact test if theoretical n < 5). The factor and covariates associated with the outcomes were subsequently tested using multivariate logistic regression. The odds ratio and the associated 95% confidence intervals are reported for these variables. P-values < 0.05 were considered significant. Analyses were performed with JAMOVI software, version 1.6.23 (The Jamovi Project, 2020) and with Prism Software v7 (GraphPad).

3. Results

3.1. Study population

A total of 825 SOT recipients were included (Table 1): 46.2% had received a kidney transplantation, 35.3% a liver transplantation, 10.8% a heart transplantation, and 7.7% a lung transplantation. Median age at the time of the first vaccination (D1) of SARS-CoV-2 vaccine was 61.2 (IQR 50.9–69.3) years; median time since receiving a transplant was 6.7 years (IQR 3.3–11.9); 66.7% of patients were male. Regarding the number of doses of SARS-CoV-2 vaccine, 94.6% of patients received three doses or more, including 63.4% of patients with four doses or more. More than 97% of the patient received BNT162b2 vaccine (as a result, we did not explore the impact of the type of vaccine received). The median delay between two consecutive doses was 28 days between D1 and D2, 46.5 days between D2 and D3, and 201 days between D3 and D4 (Table 1).

3.2. Anti-SARS-CoV-2 spike antibody response

Among the 825 SOT recipients, 1083 anti-spike serological tests were carried out, including 66 after D1, 244 after D2, 538 after D3, and 235 after D4 (Fig. 1). The median delay between the dose of vaccine and the serology was the shortest after D1 (28 days) and after D4 (31.5 days), then after D2 (68 days), and the longest after D3 (122 days) (Table 2). The proportion of participants with a strong humoral response (>260 BAU/mL) increased with the number of doses: 10.6% after D1, 35.1% after D2, 48.5% after D3, and 65.1% after D4 (p < 0.001). However, 23.8% of SOT recipients remained seronegative after D4 (Fig. 1).

Similar results were observed when considering each type of SOT recipient separately (Table 2): the proportion of patients with a detectable humoral response increased after each dose of vaccine, even though between 43.3% and 43.3% remained seronegative after D4 (depending of organ transplanted). A higher proportion of strong humoral responders was observed for liver transplant recipients whatever the number of SARS-CoV-2 vaccine injections received (Table 2). Liver transplant recipients (Table 3) compared to other transplant recipients were older at the time of transplantation (57.4 vs 58.7 years-old, p < 0.001), at the time of D1 (63.7 vs 58.7 years-old, p < 0.001), higher proportion of male (73.5% vs 62.9%, p = 0.002), had higher delay between D3–D4 (213 vs 195 days, p < 0.001) and higher delay between dose of vaccine and serology than other transplant recipients.

The multivariate analysis model included after checks of confounders: type of transplant, age at D1, sex, and the delay between doses of vaccine and the serology. After D2 and D3, liver transplantation and young age were independently associated with a strong humoral response (Table 4). After D4, only liver transplantation was independently associated with a strong humoral response (Table 4).

3.3. Follow-up of the humoral response

For 219 patients, at least two determinations of the anti-spike antibody titers were available (after D2 and D3 for 44, and after D3 and D4 for 175; Table 5), and only nine patient had three determination of the anti-spike antibody titers (as the number is low, no analysis has been made regarding the evolution of titer between D2 then D3 then D4).

Table 1

| Characteristic | All patients (n = 825) | Kidney transplant (n = 381) | Liver transplant (n = 291) | Heart transplant (n = 89) | Lung transplant (n = 64) |
|---------------|-----------------------|-----------------------------|---------------------------|--------------------------|-------------------------|
| Gender, n (%) |                       |                             |                           |                          |                         |
| Male          | 550 (66.7)            | 235 (61.7)                  | 214 (73.5)                | 59 (66.3)                | 42 (65.6)               |
| Female        | 275 (33.3)            | 146 (38.3)                  | 77 (26.5)                 | 30 (33.7)                | 22 (34.4)               |
| Age at transplantation, median (IQR) years | 53.0 (42.5–61.9) | 51.2 (41.3–62.4) | 57.4 (48.5–62.4) | 45.1 (35.1–54.1) | 42.8 (36.2–49.1) |
| Age at D1 of vaccination, median (IQR) years | 61.2 (50.9–69.3) | 59.4 (49.3–69.0) | 63.7 (57.1–70.6) | 53.6 (47.0–64.0) | 62.0 (47.9–69.6) |
| Time between transplant and D1 of vaccination, median (IQR) years | 6.7 (3.3–11.9) | 6.3 (3.3–11.7) | 6.7 (3.0–11.2) | 7.9 (3.8–16.1) | 7.9 (4.4–11.8) |
| Number of SARS-CoV-2 vaccine doses received, n (%) | | | | | |
| 1 dose       | 4 (0.5)               | 3 (0.8)                     | 1 (0.3)                   | –                        | –                       |
| 2 doses      | 41 (5.0)              | 19 (5.0)                    | 18 (6.2)                  | 1 (1.1)                  | 1 (4.7)                 |
| 3 doses      | 257 (31.2)            | 152 (39.9)                  | 85 (29.2)                 | 8 (9.0)                  | 12 (18.8)               |
| 4 doses and more | 523 (63.4)       | 205 (54.3)                  | 187 (64.3)                | 80 (89.9)                | 49 (76.6)               |
| Time between 1st and 2nd dose, median (IQR) days | 28 (27–30) | 28 (26–29) | 28 (27–32) | 28 (28–29) | 28.5 (28–31) |
| Time between 2nd and 3rd dose, median (IQR) days | 46.5 (31–75) | 47 (30–77.5) | 42 (31–74.3) | 58 (40.5–74.3) | 42 (31–72) |
| Time between 3rd and 4th dose, median (IQR) days | 201 (173–221) | 199 (179–216) | 213 (191–231) | 160 (142–203) | 187 (171–214) |

n (%) or median delay (IQR).
Among the 37 seronegative patients before D3, 22 % developed a weak ($n = 1$) or strong ($n = 7$) humoral response after D3, whereas 78 % remained seronegative. Among the four patients with a weak humoral response before D3, two developed a strong humoral response and two a weak response after D3 (Fig. 2).

Among the 73 patients with a seronegative status before D4, 47 % developed a weak ($n = 15$) or a strong ($n = 19$) humoral response after D4, whereas 53 % remained seronegative. Among the 34 patients with a weak humoral response before D4, 29 developed a strong humoral response and five retained a weak response after D4.

The proportion of patients with a detectable humoral response was significantly higher after D4 than after D3 ($47 \%$ vs $22 \%$, $p = 0.01$).
Fewer of the patients receiving belatacept had a strong humoral response after D2 (6.5\% with belatacept vs 21.4\% with no belatacept) and after D3 (32.4\% with belatacept vs 45.1\% with no belatacept) (Supplementary Table 1).

In 96 kidney transplant recipients, at least two determinations of the anti-spike antibody levels were available (after D2 and D3 for 44, and after D3 and D4 for 52) (Supplementary Table 2). Before D3, 22 patients receiving belatacept and 14 patients without belatacept were seronegative. Fewer of the patients receiving belatacept developed a detectable humoral response after D3 compared to those not receiving belatacept (9\% vs 40\%, \(p = 0.025\)); 91\% of those receiving belatacept remained seronegative after D3. Moreover, patients under belatacept less frequently developed a strong humoral response (12\% vs 44\%, \(p = 0.021\)) (Fig. 3). Before D4, 16 patients receiving belatacept and 20 not receiving belatacept were seronegative. The same proportions of patients either receiving (\(n = 6\)) or not receiving belatacept (\(n = 7\)) had developed a detectable humoral response (38\% vs 35\%, \(p = 0.88\)). Moreover, among patients without a strong humoral response before D4, of the 18 that were receiving belatacept and the 24 not receiving belatacept, four and eight patients, respectively, developed a strong humoral response (22\% vs 33\%, \(p = 0.43\)). No difference in humoral response was observed after D4 between those receiving or not receiving belatacept.

### 4. Discussion

Herein, we have reported on the humoral immune responses of a large population of SOT recipients that received one to four doses of vaccine.

### 3.4. Effect of Belatacept on anti-SARS-CoV-2 spike antibody responses in kidney-transplant recipients

Belatacept was given to 40.5\% (\(n = 209\)) of kidney transplant recipients. Fewer of the patients receiving belatacept had a strong humoral response after D2 (6.5\% with belatacept vs 21.4\% with no belatacept) and after D3 (32.4\% with belatacept vs 45.1\% with no belatacept) (Supplementary Table 1).

| Parameters | \(p\)-value | Odds ratio | 95\% Confidence Interval |
|------------|-------------|------------|--------------------------|
| Post D2 analysis |  |  |  |
| Liver vs other transplant | < 0.001 | 5.316 | [2.648–10.67] |
| Age at D1 of vaccination | 0.103 | 0.981 | [0.959–1.00] |
| Delay between D2 and serology post D2 | 0.205 | 1.003 | [0.998–1.01] |
| Male vs Female | 0.255 | 0.705 | [0.386–1.29] |
| Post D3 analysis |  |  |  |
| Liver vs other transplant | < 0.001 | 3.677 | [2.421–5.564] |
| Age at D1 of vaccination | 0.002 | 0.977 | [0.963–0.992] |
| Delay between D3 and serology post D3 | 0.936 | 1.00 | [0.996–1.004] |
| Male vs Female | 0.110 | 1.373 | [0.931–2.024] |
| Post D4 analysis |  |  |  |
| Liver vs other transplant | < 0.001 | 6.608 | [2.887–15.126] |
| Age at D1 of vaccination | 0.049 | 0.979 | [0.958–1.00] |
| Delay between D4 and serology post D4 | 0.497 | 0.997 | [0.988–1.006] |
| Male vs Female | 0.149 | 1.563 | [0.852–2.868] |

\(p\)-value was determined by multivariate logistic regression.

### Table 3

Strong humoral response regarding liver and other transplant recipient.

| Characteristics | Liver transplant | Other transplant | \(p\)-value |
|----------------|-----------------|-----------------|------------|
| Gender, \(n\) (%) | Male | 214 (73.5) | 336 (62.9) | 0.002 |
| Age at transplantation, median (IQR) years | 77 | 198 | (26.5) | (37.1) |
| Age at D1 of vaccination, median (IQR) years | 57.4 (48.5–62.4) | 50.4 (39.4–60.8) | < 0.001 |
| Time between transplant and D1 of vaccination, median (IQR) days | 63.7 (57.1–70.6) | 58.7 (48.5–68.6) | < 0.001 |
| Time between 1st and 2nd dose, median (IQR) days | 6.7 (3.02–11.2) | 6.67 (3.43–12.3) | 0.974 |
| Time between 2nd and 3rd dose, median (IQR) days | 28 (27–32) | 28 (27–29) | 0.136 |
| Time between 3rd and 4th dose, median (IQR) days | 42 (31–74.3) | 48 (31–75.3) | 0.993 |
| Delay between D2 and serology post D2 (days) | 213 (191–231) | 195 (164–214) | 0.001 |
| Delay between D3 and serology post D3 (days) | 151 (66–193) | 48.5 (28–94.5) | 0.001 |
| Delay between D4 and serology post D4 (days) | 152 (121–173) | 91 (45–134) | 0.001 |
| Strong humoral responders after D2, \(n\) (%) | 89 (70–95) | 37 (29–67) | 0.001 |
| Strong humoral responders after D3, \(n\) (%) | 43 (65.2) | 42 (23.6) | 0.001 |
| Strong humoral responders after D4, \(n\) (%) | 145 (65.6) | 116 (36.6) | 0.001 |
| Strong humoral responders after D4, \(n\) (%) | 61 (87.1) | 92 (55.8) | 0.001 |

\(p\)-value was determined by the chi-square test for categorical data (or Fisher’s exact test if theoretical \(n < 5\)) and for continuous data the ANOVA Welch’s test (or Fisher’s test if variances were assume equal).

### Table 5

Follow-up of the humoral response after three and four doses of vaccine.

| Serology profile after D2 | Serology profile after D3 | Number of patients | Serology profile after D3 | Serology profile after D4 | Number of patients |
|---------------------------|---------------------------|--------------------|---------------------------|---------------------------|--------------------|
| Seronegative (\(n = 37\)) | Seronegative | 29 | Seronegative (\(n = 73\)) | 39 | 19 |
| | Weak humoral response | 8 | | | |
| | Strong humoral response | | | | |
| Weak humoral response (\(n = 4\)) | Seronegative | – | Weak humoral response (\(n = 34\)) | 5 | 29 |
| | Weak humoral response | 2 | | | |
| | Strong humoral response | 2 | | | |
| Strong humoral response (\(n = 3\)) | Seronegative | – | Strong humoral response (\(n = 68\)) | 2 | 2 |
| | Weak humoral response | 3 | | | |
| | Strong humoral response | | | | |
of COVID-19 vaccine. Our primary aim was to assess the benefits of the different doses.

As immunocompromised patients were excluded from the initial clinical trials that led to marketing authorization for the COVID-19 vaccine, their immune responses after vaccination had to be assessed. Several trials have been conducted regarding immunogenicity after one or two doses of vaccine [10–14]: these have reported a detectable humoral response of 17 % after one dose, and responses ranging from 34.5 % to 62.0 % after two doses. More recently, a third dose has been shown to increase the proportion of patients with a detectable anti-spike antibodies by 26.5 % [15] to 49 % [27], which is close to the increase we reported in our study (18.1 %). Moreover, we observed that 32.3 % of patients remained seronegative after D3, which is similar to that previously reported (33.7 % in 872 SOT recipients [28] and 23.1 % in 396 SOT recipients [15]).

Only a few reports are available regarding the effect of a D4 in SOT recipients. Kamar et al. [16] reported that 41.0 % of their 32 seronegative patients after D3 had a humoral response after a D4, for Alejo et al. [17] it was 57.0 % of their patients, for Karaba et al. [29] 62.5 %, and for Masset et al. [19] 42.8 %, with only 8.1 % of patients with a strong humoral response. In addition, Benotmane et al. [18] reported that 81 % of patients with a weak immune response after the third dose displayed a strong anti-RBD IgG response after the fourth injection. Overall, these results are close to our observations: on the 73 patients seronegative after D3, 47 % had developed humoral response after D4. Taken together, these previous results and ours should encourage the use of a fourth dose given to all SOT recipients that have not responded after a D3.

Some teams previously reported better humoral response in liver transplant recipient. First, Nazaruk et al. reported higher humoral response in liver versus kidney transplant dependent of age, type of transplant et immunosuppression [30]. Second, Balsby et al. reported that liver transplant, age and immunosuppression were associated with antibody response to the BNT162B2 vaccine [31]. Our results suggest a better humoral response to COVID-19 vaccine in liver transplant recipient, as the highest proportion of strong humoral responders after each dose of COVID-19 vaccine was observed in this population. This is likely to result from immunosuppressive regimen differences between the different types of transplants, with a less heavy immunosuppressive treatment in liver transplant. Indeed, the immunosuppression protocol used in liver transplantation is routinely composed of anticalcineurins alone quickly after transplantation, whereas the protocols classically used in other types of transplantation are based on a combination of anticalcineurins, antimetabolic and low-dose corticosteroid therapy.
Belatacept use in kidney-transplant recipients appears to improve glomerular-filtration rates through an absence of nephrotoxicity and possibly graft survival. However, belatacept is associated with others issues: e.g., humoral responses to seasonal influenza vaccination in patients under a belatacept-containing regimen are impaired [32]. This is in line with our observation that kidney-transplant recipients have less frequently a detectable humoral response after D3 if they have received belatacept (9%) compared to patients on a belatacept-free regimen (40%). A previous study conducted on kidney-transplant recipients reported similar results [33], with 20% of patients receiving belatacept developing a vaccine humoral response after a third dose of vaccine compared to 68% of those not receiving belatacept. Another study showed an even lower rate of vaccine humoral response after a third dose (6.4%) for kidney-transplant recipients receiving belatacept [34]. These results suggest that patients receiving belatacept should be informed early-on of the potential use of prophylactic neutralizing antibodies in case of weak vaccine response.

Our study has several limitations. Firstly, its retrospective design may have led to heterogeneous data, although we could include a relative high number of patients in the study. Second, the delay between vaccine injection and serology testing was heterogeneous. Third, all anti-Spike antibody level determination were not conducted within the same laboratory; however, the results could be compared after adjustment to the same WHO international standard and the calibration controls provided by the manufacturers, which limits the heterogeneity of our results [35,36]. It should also be noted that a threshold of 260 BAU/mL was used to classify our patients (weak/strong humoral response to COVID-19 vaccines), but this is disputable. Indeed, this threshold was considered potentially protective against Alpha VOC, and it is highly likely that the protective values against Delta and Omicron VOC are higher due to the immune escape they displayed [21,37]. Moreover, this threshold has been obtained in a study analyzing immunocompetent subjects, and may have a different, higher value in immunocompromised patients. Therefore, we cannot conclude that the patients we classified as having a strong immune response are efficiently protected during the current Omicron circulation; our conclusions could have differed on this point if he had assessed the neutralizing antibody titers. Moreover, it could also be of interest to explore anti-SARS-CoV-2 cellular immune response which is an effector for preventing severe disease [38]. Finally, we cannot rule out reinfection events, which may interfere with the kinetic of the patients’ humoral response. However, this study represents the largest cohort of SOT recipients analyzed for their immune responses after receiving between one and four dose(s) of COVID-19 vaccine.

5. Conclusion

This study shows that the proportion of SOT recipients with a strong humoral response increase with the number of doses of COVID-19 vaccine received, including the fourth vaccination, even for patients receiving belatacept. Thus, a fourth dose of vaccine should be systematically proposed to patients that did not develop a strong immune response with the previous doses.

Funding

“The authors declare no funding.”

CRediT authorship contribution statement

Julien Lupo: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft.

Q. Perrier: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – review & editing.

Caroline Augier: Data curation, Writing – review & editing.

Loïc Falque: Data curation, Writing – review & editing.

Laurent Pelletier: Data curation, Writing – review & editing.

Pierrick Bedouch: Data curation, Writing – review & editing.

Myriam Blanc: Data curation, Writing – review & editing.

Christel Saint-Raymond: Data curation, Writing – review & editing.

Aude Boignard: Data curation, Writing – review & editing.

Olivier Epaulard: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing – original draft.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.vaccine.2022.08.065.

References

[1] Kates OS, Haydel BM, Florman SS, Rana MM, Chaudhry ZS, Ramesh MS, et al. Coronavirus disease 2019 in solid organ transplant: A multicenter cohort study. Clin Infect Dis 2021;73(11):e4090–9.
[2] Pereira MR, Arcassy S, Fain MA, Mohan S, Emond JC, Tsapepas DS, et al. Outcomes of COVID-19 in solid organ transplant recipients: A matched cohort study. Transpl Infect Dis 2021;23(4):e13637. https://doi.org/10.1111/tid.13637.
[3] Polack FP, Thomas SJ, Kitchin N, Absalon J, Curtiss R, Lynch M, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 2020;383(27):2603–15.
[4] Baden LR, El Sahly HM, Essink B, Koteloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 2021;384(5):403–16.
[5] Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and Efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond Engl 2021;397(10269):99–111.
[6] Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Curtiss R, et al. Safety and efficacy of a third dose of BNT162b2 Covid-19 vaccine. N Engl J Med 2022;386(20):1910–21.
[7] Mogen O, Wxman JG, Makov-Assif M, Vered R, Dicker D, Hernán MA, et al. Fourth dose of BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med 2022;386(7):1603–14.
[8] Chong PP, Avery RK. A comprehensive review of immunization practices in solid organ transplant and hematopoietic stem cell transplant recipients. Clin Ther 2017;39(8):1581–98. https://doi.org/10.1016/j.clinthera.2017.07.005.
[9] Chong PP, Handler L, Weber DJ. A systematic review of safety and immunogenicity of influenza vaccination strategies in solid organ transplant recipients. Clin Infect Dis Off Publ Infect Dis Soc Am 2018;66(11):1802–11. https://doi.org/10.1093/cid/cix108.
[10] Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA 2021;325(17):1784.
[11] Hallatt AM, Greenberg RS, Boyarsky BJ, Shah PD, Ou MT, Teles AT, et al. SARS-CoV-2 messenger RNA vaccine antibody response and reactivity against heart and lung transplant recipients. J Heart Lung Transplant 2021;40(12):1579–88.
[12] Hall VG, Ferreira VH, Ierullo M, Ku T, Marinelli T, Majchrzak-Kita B, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. Am J Transplant 2021;21(12):3980–9.
[13] Boyarsky BJ, Werbel WA, Avery RK, Tobian AAR, Massie AB, Segev DL, et al. Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. JAMA 2021;325(21):2204.
[14] Russo G, Lai Q, Poli L, Pernone MP, Gaeta A, Rossi M, et al. SARS-CoV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications. Clin Transplant 2022;36 (1).
[15] Del Bello A, Abravanel F, Marion O, Couat C, Esposito L, Lavayssières L, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. Am J Transplant 2022;22(1):322–3.

[16] Kamar N, Abravanel F, Marion O, Romieu-Mourrez R, Couat C, Del Bello A, et al. Assessment of 4 doses of SARS-CoV-2 messenger RNA-based vaccine in recipients of a solid organ transplant. JAMA Netw Open 2021;4(11):e2136030.

[17] Alejo JL, Mitchell J, Chiang T-Y, Abedon AT, Aley PK, Bibi S, et al. Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: A case series. Transplantation 2021;105(12):e2880–1.

[18] Benetonne I, Bruel T, Planas D, Farf-Kremer S, Schwartz O, Caillard S. A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients. Kidney Int. 2022; 50085-253822.00168-5 [Published online February 26]. doi: 10.1016/j.kint.2022.02.011.

[19] Masset C, Benotmane I, Dantal J, Garandeau C, Gauthier-Vargas G, Cantarovich D, et al. A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients. Kidney Int. 2022;104(4):825–6.

[20] Caillard S, Thaunat O, Benetonne I, Masset C, Blanc C. Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: A case series. Ann Int Med 2022;175(3):455–6. https://doi.org/10.7326/1214.05598.

[21] Midttvedt K, Vaage JT, Heldal K, Munteh IA, Lund-Johansen F, Åsberg A. Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response. Am J Transplant. Published online May 9, 2022. doi:10.1111/ajt.17091.

[22] Chapuy-Regaud S, Middougé M, Abravanel F, Da Silva I, Porcheron M, Fillaux J, et al. Evaluation of three quantitative anti-SARS-CoV-2 antibody immunoassays. Microbiol Spectr 2021;9(3):e0137621. https://doi.org/10.1128/microbiolspectrum.01376-21.

[23] WHO. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. Accessed July 20, 2022. https://www.who.int/publications/m/item/WHO-BS-2020.2403.

[24] Epstein DB, Nilsson AC, Möller S, Lindvig SO, Davidsen JR, Abazi R, et al. Efficiency of a boost with a third dose of anti-SARS-CoV-2 antibody. Accessed July 20, 2022. https://www.who.int/publications/m/item/WHO-BS-2020.2403.

[25] Epaulard O, Buisson M, Nemoz B, Maréchal ML, Terzi N, Payen J-F, et al. Unexpectedly high efficacy of SARS-CoV-2 BNT162b2 vaccine in liver versus kidney transplant recipients—is it related to immunosuppression only? Vaccines 2021;9(12):e1454.

[26] Balsby D, Nilsson AC, Möller S, Lindvig SO, Davidsen JR, Abazi R, et al. Determinants of antibody response to a third SARS-CoV-2 mRNA vaccine dose in solid organ transplant recipients: results from the prospective cohort study COVAC-Tx. Vaccines 2022;10(4):565.

[27] Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovic A, Marculescu R, et al. Anti-spike protein assays to determine SARS-CoV-2 antibody levels: a head-to-head comparison of five quantitative assays. Microbiol Spectr 2021;9(1):e0024721. https://doi.org/10.1128/microbiolspectrum.00247-21.

[28] Saker K, Escuret V, Pittet V, Massardier-Pilonchéry A, Paul S, Mokdad B, et al. Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of standardized titers in vaccinated health care workers. J Clin Microbiol 2022;60(1):e0174621. https://doi.org/10.1128/JCM.01746-21.

[29] Dineglio C, Miguees M, Chapuy-Regaud S, Da-Silva I, Jougla I, Pradere C, et al. Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response. J Infect 2022;85(1):e4–6.

[30] Cromer D, Juno JA, Khoury D, Reynolds A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. Nat Rev Immunol 2021;21(6):395–404.